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Pbx Proteins in Cryptococcus neoformans Cell Wall Remodeling and
Capsule Assembly
Pardeep Kumar,a Christian Heiss,b Felipe H. Santiago-Tirado,a Ian Black,b Parastoo Azadi,b Tamara L. Doeringa
Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USAa; Complex Carbohydrate Research Center, University of
Georgia, Athens, Georgia, USAb
The cryptococcal capsule is a critical virulence factor of an important pathogen, but little is known about how it is associated
with the cell or released into the environment. Twomutants lacking PBX1 and PBX2were found to shed reduced amounts of the
capsule polysaccharide glucuronoxylomannan (GXM). Nuclear magnetic resonance, composition, and physical analyses showed
that the shedmaterial was of normal mass but was slightly enriched in xylose. In contrast to previous reports, this material con-
tained no glucose. Notably, the capsule fibers of pbxmutant cells grown under capsule-inducing conditions were present at a
lower than usual density and were loosely attached to the cell wall. Mutant cell walls were also defective, as indicated by pheno-
types including abnormal cell morphology, reducedmating filamentation, and altered cell integrity. All observed phenotypes
were shared between the twomutants and exacerbated in a double mutant. Consistent with a role in surface glycan synthesis, the
Pbx proteins localized to detergent-resistant membrane domains. These results, together with the sequence motifs in the Pbx
proteins, suggest that Pbx1 and Pbx2 are redundant proteins that act in remodeling the cell wall to maintain normal cell mor-
phology and precursor availability for other glycan synthetic processes. Their absence results in aberrant cell wall growth and
metabolic imbalance, which together impact cell wall and capsule synthesis, cell morphology, and capsule association. The sur-
face changes also lead to increased engulfment by host phagocytes, consistent with the lack of virulence of pbxmutants in animal
models.
The basidiomycetous yeast Cryptococcus neoformans is ubiqui-tous in the environment and is most commonly associated
with bird excreta (1–3). In recent years, this yeast has emerged as
an important opportunistic pathogen of humans. Cryptococcosis
poses a particular challenge in the developing world, where large
populations of individuals are immunocompromised due to HIV
infection in the context of limited health care resources. These
factors contribute to a global death toll due to cryptococcal infec-
tion that was recently estimated to exceed 625,000 per year (4).
Cryptococcosis is initiated by inhalation of airborne infectious
particles, either basidiospores or desiccated yeast cells (5). In
healthy individuals, C. neoformans is either cleared or causes a
latent infection, but in the context of immune compromise, this
facultative intracellular pathogen can multiply and disseminate
throughout the body; its ability to cross the blood-brain barrier
leads to a frequently fatal meningoencephalitis (6).
The virulence ofC. neoformans is attributed to multiple factors
that include its ability to grow at human body temperature and
inhibit phagocytosis; the secretion of proteases, phospholipase,
and urease; melanin synthesis; and the elaboration of a polysac-
charide capsule (7–9). The capsule is a dynamic structure sur-
rounding the cell wall that dramatically increases in thickness dur-
ing infection, up to many times the cell radius. Capsule
polysaccharide is also shed constitutively into the extracellular
environment and impedes host responses to cryptococcal infec-
tion by inhibiting phagocytosis, altering antigen presentation,
changing cytokine synthesis, and inhibiting leukocyte migration
to the sites of inflammation (10).
The C. neoformans capsule is a complex structure composed of
two high-molecular-mass polysaccharides, glucuronoxyloman-
nan (GXM; 90% of the mass) and glucuronoxylomannogalac-
tan (GXMGal; 7 to 8% of the mass), together with a small
amount of mannoproteins (10–12). Purification of capsule poly-
saccharides shed from cryptococcal cells grown in vitro has en-
abled detailed structural studies of these components. GXM is a
linear -1,3-linked mannan of 1 to 7 MDa (13) whose mannose
residues are variably O-acetylated and substituted with glucuronic
acid and xylose (14). GXMGal is an -1,6-galactan of roughly
100,000 Da. Alternate galactose residues of the linear backbone
are branched with short side chains of galactose and mannose,
which may be further substituted with xylose and glucuronic acid
(15, 16); the branching backbone residues may be additionally
substituted with galactofuranose (17) (other residues are all of the
pyranose form). Both of the capsule polysaccharides demonstrate
structural heterogeneity, depending on the strain and growth con-
ditions (18, 19), and both have been implicated in cryptococcal
pathogenesis (20, 21).
The synthesis of capsule polysaccharides and construction of
the capsule involve multiple steps and significant metabolic in-
vestment (12, 22, 23). We previously reported that capsule poly-
saccharide synthesis occurs intracellularly, with the products sub-
sequently being transported to the cell surface via elements of the
protein secretory pathway (24). Once capsule polysaccharides exit
the cell, they become associated with its surface (25). Little is
known about the specific mechanisms of this interaction, al-
though we have shown that it depends on cell wall -1,3-glucan
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(26, 27). Consistent with this finding, deletion of the gene encod-
ing -1,3-glucan synthase (AGS1) yields acapsular cells that can-
not bind GXM, although they do shed capsule polysaccharide like
wild-type cells (27). Other investigators have suggested that chi-
tin, another cell wall component, is also involved in capsule as-
sembly (28, 29).
To identify additional factors involved in capsule assembly, we
screened mutant cryptococci using a capsule transfer assay. This
assay is based on the observation that exogenous capsule polysac-
charide, such as the material shed from wild-type cells, is able to
bind to the surfaces of acapsular mutant strains of C. neoformans
(e.g., the cap59 mutant) (26, 30). We tested a library of crypto-
coccal deletion mutants (31) for their display of surface capsule
and their ability to serve as capsule donors in this transfer assay.
Strains lacking the genes PBX1 and PBX2 showed defects in both
surface capsule and capsule transfer in our screen. It has previ-
ously been reported that these mutants have reduced virulence in
mice (32), highlighting the importance of investigating the func-
tion of the encoded proteins. We found that these mutants addi-
tionally exhibit morphological defects, reduced capsule synthesis
and association, and increased uptake by mammalian phagocytes.
We hypothesize that the Pbx proteins act at the membrane in cell
wall remodeling, such that their absence leads to this constellation
of phenotypes.
MATERIALS AND METHODS
Reagents. Difco medium components were from BD (Becton, Dickinson
and Company, Sparks, MD), DNA polymerases (Taq and AccuPrime Pfx)
and Escherichia coli DH5 competent cells were from Invitrogen (by Life
Technologies Corporation), oligonucleotides were from Invitrogen or
Sigma-Aldrich Co. LLC (St. Louis, MO), reagents for DNA isolation and
biolistic transformation were from Bio-Rad Laboratories Inc., and restric-
tion enzymes were from Invitrogen or New England BioLabs Inc. Kits for
purification of DNA fragments and PCR products were from Qiagen,
In-Fusion HD cloning kits were from Clontech Laboratories Inc.,
nourseothricin (ClonNat) was from Werner BioAgents (Germany), and
G418 (Geneticin) was from Invitrogen. Specialty reagents for electron
microscopy were from Polysciences Inc. or Ted Pella Inc., and colloidal
gold-conjugated antibody was from Jackson ImmunoResearch Laborato-
ries Inc., West Grove, PA. All other reagents or chemicals were from
Sigma. Murine monoclonal anti-GXM antibodies 3C2 and 2H1 were gen-
erous gifts from Thomas Kozel (University of Nevada, Reno, NV) and
Arturo Casadevall (Albert Einstein College of Medicine, Bronx, NY), re-
spectively.
Culture conditions and strains. C. neoformans strains were stored at
80°C in 25% glycerol and streaked onto yeast extract peptone dextrose
(YPD) agar (1% [wt/vol] yeast extract, 2% [wt/vol] peptone, 2% [wt/vol]
dextrose, 2% agar) plates for growth at 30°C. Liquid cultures were grown
at 30°C with shaking at 230 rpm in YPD broth or in capsule induction
medium (CIM; 0.17% [wt/vol] yeast nitrogen base without amino acids
and ammonium sulfate, 0.15% [wt/vol] asparagine, 2% [wt/vol] glucose,
12 mM NaHCO3, 35 mM MOPS [morpholinepropanesulfonic acid],
pH 7.1). As appropriate, media were supplemented with 100 g/ml
nourseothricin or G418. E. coli strains were grown at 37°C in Luria broth
(LB; 1% [wt/vol] tryptone, 0.5% [wt/vol] yeast extract, 1% [wt/vol] NaCl)
with shaking (230 rpm) or on LB agar plates (LB with 2% agar). As ap-
propriate, the medium included 100 g/ml ampicillin or 60 g/ml kana-
mycin. The fungal strains used in this work are listed in Table 1. Wild-type
(WT) KN99 MAT and MATa strains were provided by Joseph Heitman
(Duke University Medical Center, Durham, NC) (33), an acapsular
cap59 strain (in the KN99 background) was provided by Jennifer K.
Lodge, Washington University Medical School (34), and the ags1 strain
was from our previous work (27). Other strains used in this study (Table
1) were generated as described below.
Genetic manipulations. The coding sequences of PBX1 (CNAG_
01172.1) and PBX2 (CNAG_05562.1) were identified from the C. neofor-
mans (serotype A strain H99) genome sequence available at http://www
.broad.mit.edu/annotation/genome/cryptococcus_neoformans/Home
.html. These were replaced by drug resistance markers according to the
split marker strategy (35) shown in Fig. S1 in the supplemental material,
using the primers listed in Table S1 in the supplemental material. Roughly
1-kb segments of the 5= and 3= untranslated regions (UTRs) of each gene
were amplified from KN99 genomic DNA isolated as described previ-
ously (36). Drug resistance marker segments were amplified from plas-
mids pMH12-T (from Jennifer K. Lodge, Washington University Medical
School) and pGMC200 (from Gary Cox, Duke University Medical Cen-
ter) for G418 (37) and nourseothricin (38), respectively. PCR was used to
fuse the upstream flank of each gene of interest with the 3= part of the
marker and the downstream flank with the 5= part of the marker.
The fusion PCR products were biolistically transformed into KN99
as described in reference 39, with the expectation that homologous re-
combination events involving each flank and the overlapping region of
the marker segments (500 bp) would yield replacement of the targeted
gene by the marker (in reverse orientation; see Fig. S1 in the supplemental
material). For biolistics, KN99 cells were grown in YPD broth to late log
phase and harvested by centrifugation, and thick cell suspensions were
plated as circular lawns at the center of YPD agar plates. The plates were
incubated at 30°C for 3 h and then bombarded with 0.6-m gold beads
coated with DNA of the target construct (1.5 g total) using a model
PDS-1000/He biolistic particle delivery system (Bio-Rad Laboratories
Inc.). After overnight growth, cells were transferred to selective YPD agar
plates and individual colonies were screened by PCR to assess correct
integration. Three independent strains were also confirmed to have each
deletion by DNA blotting, using an AlkPhos direct labeling and detection
system with a CDP-Star kit (GE Healthcare) according to the manufac-
turer’s instructions. Ten-microgram aliquots of genomic DNA from WT
KN99 and three independent pbx1 and pbx2 mutants were digested
with HindIII and XhoI (which cuts within the PBX1-coding sequence but
not that of the G418 resistance cassette) or BamHI and PvuII (which cuts
within the PBX2-coding sequence but not that of the nourseothricin re-
sistance cassette) and blotted using standard techniques (40) with probes
corresponding to the 5= or 3= flanking regions of the PBX1 and PBX2
genes. These blots confirmed the gene replacement and that the marker
cassette was present only once in the genome with no additional ectopic
insertions (data not shown). The same approach was used to delete PBX1
and PBX2 in the cap59mutant background for use in GXMGal isolation
(see below). A pbx double mutant was also generated by deleting PBX2 (as
above) in a pbx1mutant strain.
To reconstitute confirmed pbx1 and pbx2mutants, wild-type PBX
sequences, including1-kb flanking regions at both ends, were amplified.
PCR was used to incorporate sequences for nourseothricin and G418
TABLE 1 Strains used in this study
Strain descriptiona Drug(s) used for selection
Reference
or source Strain
KN99 33 WT KN99
KN99 MATa 33 WT KN99a
KN99 cap59 Hygromycin 34 cap59mutant
JEC21 ags1 Nourseothricin 27 ags1mutant
KN99 pbx1 G418 This study pbx1mutant
KN99 pbx2 Nourseothricin This study pbx2mutant
KN99 pbx1 pbx2 G418, nourseothricin This study pbx1 pbx2mutant
KN99 pbx1::PBX1 Nourseothricin This study pbx1::PBX1 mutant
KN99 pbx2::PBX2 G418 This study pbx2::PBX2 mutant
KN99/pPBX1-HA Nourseothricin This study Pbx1-HA
KN99/pPBX2-HA Nourseothricin This study Pbx2-HA
KN99 cap59 pbx1 Hygromycin, G418 This study cap59 pbx1mutant
KN99 cap59 pbx2 Hygromycin, nourseothricin This study cap59 pbx2mutant
a All strains not otherwise designated were MAT.
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resistance after the 3= ends of the PBX1 and PBX2 amplicons, respectively,
followed by another1 kb of appropriate 3= flanking sequence (details are
available on request). Biolistic transformation was then carried out using
a gene replacement strategy (similar to that described above) to incorpo-
rate the PBX sequences at their original loci.
Epitope tagging of Pbx1 and Pbx2. To episomally express tagged Pbx
proteins, we constructed plasmids in which the PBX1 and PBX2 genes
were modified by the addition of a sequence encoding a triple hemagglu-
tinin (HA) epitope tag at the 3= end. Briefly, an empty expression cassette
was first assembled by PCR amplifying the ACT1 promoter and TRP1
terminator regions from C. neoformans KN99 genomic DNA using
primers MSPC114 and MSPC115 and primers MSPC116 and MSPC117,
respectively (primer sequences are provided in Table S1 in the supple-
mental material). The resulting amplicons were then fused by overlap
PCR, using 5= phosphorylated primers, to a synthetic spacer consisting of
PmlI and MreI restriction sites, three copies of the HA sequence, and a
stop codon. For drug selection, a fragment encoding the cryptococcal
ACT1 promoter driving the NAT-coding sequence was released from
plasmid pGMC200 (38) using PmeI and EcoRI and ligated to the PsiI and
EcoRI restriction sites of plasmid pIBB103 (41). The resulting vector was
digested with HpaI and ligated to the empty expression cassette contain-
ing theC. neoformans ACT1 promoter andTRP1 terminator. This expres-
sion plasmid was termed pMSC-043. The PBX1- and PBX2-coding re-
gions were then PCR amplified fromC. neoformansKN99 genomic DNA
using primers PK201 and PK202 and primers PK203 and PK204, respec-
tively, thereby incorporating PmlI and MreI restriction sites. The prod-
ucts were digested with PmlI and MreI and ligated to the corresponding
sites of plasmid pMSC-043 to incorporate the three copies of the HA tag in
frame with the 3= end of each coding sequence before the stop codon. The
resulting plasmids, pPBX1-HA and pPBX2-HA, respectively, were trans-
formed into DH5 cells for sequence confirmation, and plasmids with
correct sequences were used to transform C. neoformans KN99 by elec-
troporation for episomal expression. To do this, 3 108 cells in early log
phase were transformed with 1 to 5 g of DNA as described previously
(42), with parameters set at 0.5 kV, 25 F, and resistance of 1,000 .
Transformed cells were grown in liquid YPD for 2 h at 30°C and then
plated for drug selection.
Capsule transfer.Capsule transfer assays were performed as described
in reference 26, using the cap59 acapsular strain as the capsule acceptor
and conditioned medium (CM) from 5-day-old cultures of KN99 or
other indicated strains as the capsule donor. Acceptor cells were grown
overnight, harvested by centrifugation, and washed twice with phosphate-
buffered saline (PBS). Cells (5  106) were diluted to 499 l with PBS,
mixed with 1 l CM (or medium control), and rotated for 1 h at room
temperature (RT). After transfer, the acceptor cells were sedimented by
centrifugation and washed twice with PBS. To visualize capsule acquisi-
tion by the acceptor cells, or endogenous capsule on other strains, the cells
were further incubated for 1 h at RT with a final concentration of 8g/ml
of anti-GXM antibody 3C2 that had been conjugated to a fluorophore
(Cy3 monoreactive dye from GE Healthcare, used according to the man-
ufacturer’s recommendations). Stained cells were washed twice with PBS,
resuspended in PBS, and examined on a Zeiss Axioskop 2 MOT Plus
wide-field fluorescence microscope; all samples from each experiment
were imaged with identical acquisition settings.
Capsule induction. Overnight cultures of C. neoformans in YPD were
harvested by centrifugation, washed twice with Dulbecco’s modified Ea-
gle’s medium (DMEM), and resuspended at 2 106 cells/ml in DMEM.
One milliliter of the suspension was incubated at 37°C with 5% CO2 for 36
h in a 24-well tissue culture plate. Cells were harvested by centrifugation,
washed once with deionized water (diH2O), and resuspended in 1 ml
diH2O. Eight microliters of the cell suspension was mixed with 2 l of
India ink stain, and 6 l of the mixture was spotted on a microscope slide
for bright-field image acquisition on a Zeiss Axioskop 2 MOT Plus wide-
field fluorescence microscope. In some experiments, cells were sonicated
for 10 s using a Fisher sonic dismembrator at 35% output before India ink
staining.
Phenotypic assays. To measure growth, cells were grown in YPD or
CIM at 30°C or 37°C with shaking as described above. Samples were
collected at regular intervals, and the cell number was assessed using a
Cellometer Auto M10 automated cell counter (Nexcelom Bioscience). For
plate assays, C. neoformans strains were grown to mid-log phase in YPD
broth and diluted to 107 cells/ml, and five 10-fold serial dilutions were
made. Five microliters of each dilution was spotted onto solid medium
plates, which were incubated at 30°C, 37°C, or 39°C. The solid media
tested included YPD containing NaCl (0.1, 0.5, or 1.2 M), SDS (0.01, 0.03,
or 0.06%), caffeine (1, 5, or 15 mM), Congo red dye (0.1 or 0.5% from a
4% stock solution prepared in 50% ethanol), or calcofluor white (0.5, 1.0,
or 1.5 mg/ml). Growth on various carbon sources was checked on mini-
mal medium (0.17% [wt/vol] yeast nitrogen base without amino acids
and ammonium sulfate, 0.5% [wt/vol] ammonium sulfate, 2% [wt/vol]
agar) containing 2% (wt/vol) of the desired carbon source (glucose,
galactose, or xylose).
Melanin synthesis was assessed by growing cells on glucose-free aspar-
agine agar plates (0.1% [wt/vol] L-asparagine, 0.05% [wt/vol] MgSO4,
0.3% [wt/vol] KH2PO4, 0.0001% [wt/vol] thiamine, 1 mM L-3,4-dihy-
droxyphenylalanine [L-DOPA], 2% [wt/vol] Bacto agar) in the dark at
30°C, 37°C, or 39°C and examining them on days 2 through 5 for
melanization, seen as a brown colony color. To compare melanin reten-
tion in KN99 and mutant cell walls, cells grown overnight in the same
medium without agar were collected, washed once in the same medium,
and counted. Cells (108) were inoculated into 2 ml of fresh medium in
10-ml culture tubes in triplicate and shaken at 30°C for 24 h. Following
incubation, the culture tubes were centrifuged at 3,000 g for 10 min and
photographed to visualize the cell wall-associated melanin in the cell pel-
let; the optical density at 400 nm of the supernatant fraction was also
recorded to assess melanin release from the cells into the growth medium
(34).
Electron microscopy. Overnight cultures were diluted to 2  106
cells/ml in YPD, grown for 9 h at 30°C, collected by centrifugation, quickly
resuspended in 1 ml of primary fixation mix (0.1 M sorbitol, 1 mM MgCl2,
1 mM CaCl2, 2% glutaraldehyde in 0.1 M PIPES [piperazine-N,N=-bis(2-
ethanesulfonic acid)] buffer, pH 6.8 [43]), and fixed overnight at 4°C. For
ultrastructural analysis, cells were fixed in 2% glutaraldehyde (Poly-
sciences Inc., Warrington, PA) in 100 mM phosphate buffer, pH 7.2, for 1
h at room temperature, washed in the same buffer, and postfixed in 1%
osmium tetroxide (Polysciences Inc.) for 1 h. Samples were then rinsed in
the same buffer, followed by dehydration in a graded series of ethanol and
propylene oxide prior to embedding in Eponate 12 resin (Ted Pella Inc.,
Redding, CA). Sections of 90 nm were cut with a Leica Ultracut UCT
ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained
with uranyl acetate and lead citrate, and viewed on a JEOL 1200EX trans-
mission electron microscope (JEOL USA Inc., Peabody, MA).
For immunoelectron microscopy, cells were fixed in glutaraldehyde as
described above, washed three times in 50 mM citrate buffer, pH 6.0, and
resuspended in 1 ml of 40 mg/ml lysing enzymes (L1412; Sigma) in the
same buffer to partially digest the cell wall. After 30 min of incubation at
30°C, cells were washed in 0.1 M phosphate buffer and postfixed, and
blocks were prepared as described above. Sections were blocked for 30
min with a solution of 5% fetal bovine serum in 100 mM PIPES buffer (pH
7.0), labeled for 1 h with an anti-GXM monoclonal antibody (2H1),
washed in blocking buffer, and incubated with 12-nm gold-conjugated
goat anti-mouse IgG antibody (Jackson ImmunoResearch Laboratories
Inc., West Grove, PA). Sections were then washed once in 100 mM PIPES
buffer, pH 7.0, and twice in diH2O, stained with uranyl acetate and lead
citrate, and viewed as described above.
Purification of GXM. For GXM purification, cells were inoculated
into 200 ml of CIM and grown for 5 days at 30°C with shaking. The
cultures were autoclaved and centrifuged at 18,000 g for 1 h at RT, and
the supernatant fraction was filtered through a 0.22-m-pore-size mem-
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brane filter and used for GXM purification. Purification, based on precip-
itation of the negatively charged GXM with the cationic detergent cetyl-
trimethylammonium bromide (CTAB), was performed as described
previously (22, 44).
Purification of GXMGal. GXMGal was purified following the proce-
dure described for the serotype D cap67 strain (16, 22). YPD medium
(200 ml) was inoculated with the cap59, cap59 pbx1, or cap59 pbx2
mutant strain and incubated at 30°C with shaking for 5 days. Cells were
sedimented (8,000  g, 10 min, RT), and the supernatant fraction was
concentrated to10 ml with a Pall Jumbosep spin concentrator contain-
ing a 10-kDa-molecular-weight-cutoff membrane. The concentrated su-
pernatant was used to isolate GXMGal as described by Vaishnav et al. (16)
and Klutts and Doering (22) using a combination of affinity, anion ex-
change, and size exclusion chromatography techniques.
NMR spectroscopy. Nuclear magnetic resonance (NMR) studies of
GXM and GXMGal samples were performed as previously described (15,
22). GXM samples were dissolved in water at 5 mg/ml, sonicated to reduce
the molecular mass, and deacetylated by adjusting the pH to 11 with
concentrated NH4OH before incubation for 24 h at 25°C. Samples were
then dialyzed, lyophilized, deuterium exchanged by lyophilization from
D2O, and dissolved in 0.7 ml D2O for analysis. Proton, gradient-enhanced
correlated spectroscopy (gCOSY), total correlation spectroscopy
(TOCSY), heteronuclear single quantum correlation (HSQC), gradient-
enhanced heteronuclear multiple-bond correlation (gHMBC), and nu-
clear Overhauser effect spectroscopy (NOESY) NMR spectra were ac-
quired on a Varian Inova 500-MHz spectrometer at 70°C using standard
Varian pulse sequences. TOCSY and NOESY mixing times were 120 and
300 ms, respectively. GXMGal samples were deuterium exchanged by
dissolving the samples in D2O and lyophilization, before dissolving the
samples in 0.27 ml D2O. One-dimensional proton spectra and two-di-
mensional gCOSY, TOCSY, NOESY, gHSQC, and gHMBC spectra were
obtained on a Varian Inova 500-MHz spectrometer at 70°C using stan-
dard Varian pulse sequences. Proton chemical shifts were measured rela-
tive to the location of internal acetone (	H
 2.218 ppm, 	C
 33.0 ppm).
The relative molar amounts of GXM structural motifs were determined
from the anomeric protons of the mannose residues after Lorentz-Gauss
resolution enhancement of the proton spectra and deconvolution of the
anomeric signals by use of the line-fitting routine in Mestre-C NMR soft-
ware. The areas of the three peaks belonging to the same triad were aver-
aged.
GXMGal composition. The glycosyl composition of GXMGal was
analyzed by combined gas chromatography (GC)-mass spectrometry
(MS) of the per-O-trimethylsilyl (TMS) derivatives of the monosaccha-
ride methyl glycosides produced from the sample by acidic methanolysis
as previously described (45, 46). GXMGal samples were dissolved in wa-
ter, 20 g of inositol was added as an internal standard, and the solutions
were transferred to screw-top glass tubes and freeze-dried. Methyl glyco-
sides were prepared by heating the samples in 1 M methanolic HCl at
(80°C, 18 h), followed by re-N-acetylation with pyridine and acetic anhy-
dride in methanol (for detection of amino sugars). The samples were then
per-O-trimethylsilylated by treatment with Tri-Sil reagent (Pierce) at
80°C (0.5 h). GC-MS analysis of the TMS methyl glycosides was per-
formed both on an AT 7890N GC interfaced to a 5975C MSD system
(electron impact ionization mode) and on a Shimadzu GCMS QP 2010
plus apparatus (chemical ionization mode); separation was performed on
a Grace EC-1 bonded-phase fused-silica capillary column.
GXMmolecularmass determination. The molecular masses of GXM
were determined by multiangle light scattering (MALS) as described pre-
viously (13, 47). The dn/dc constant for GXM (change in the refractive
index of the GXM solution with the change in the GXM concentration)
was determined using an Optilab rEX refractive index detector (Wyatt
Technology Corporation) in batch mode at 25°C. The instrument was
preequilibrated in MALS buffer (150 mM sodium chloride, 20 mM
HEPES [pH 7.4], 0.01% sodium azide), and solutions prepared from an-
hydrous NaCl (0 [blank], 0.1, 0.5, 1.0, 1.2, 2.0, 3.0, 4.0, and 5.0 mg/ml)
were loaded as standards for dn/dc constant determination (0.172 ml/g for
NaCl at 690 nm). GXM samples were then prepared in the same buffer,
mixed overnight, and filtered through 0.8-m-pore-size syringe filters.
The carbohydrate concentration was determined by phenol sulfuric acid
assay (48), and 50, 100, 200, 300, 400, or 500 g/ml of GXM was loaded
onto the differential refractometer. The Astra V macromolecular charac-
terization software package (Wyatt Technology Corporation) was used to
calculate the dn/dc constant.
GXM samples in MALS buffer were loaded onto a size exclusion chro-
matography column (pore size, 300 Å; WTC-030S5; Wyatt Technology
Corporation) set up in series with a Dawn Helios II multiangle light-
scattering detector (Wyatt), an Optilab rEX differential refractive index
detector (Wyatt), and a 996 photodiode array detector (Waters). The data
were recorded for light scattering, refractive index change, and UV absor-
bance over the elution profile of GXM, and results were analyzed with the
Astra V macromolecular characterization software package (Wyatt) to
calculate the molecular mass from the light scattering and refractive index
change.
GXM immunoblotting. Immunoblotting of GXM was performed
essentially as we have previously reported (49). Briefly, 50 l of CM
from the indicated strains grown in YPD or CIM or 10 g of GXM
purified from CM of cells grown in CIM was mixed with 6 DNA
loading dye, and the mixture was loaded on a 0.6% certified megabase
agarose gel (Bio-Rad Laboratories Inc.) and subjected to electropho-
resis for 15 h at 25 V in 0.5 TBE (44.5 mM Tris base, 44.5 mM boric
acid, 1 mM EDTA, pH 8.3). The gel was transferred onto a positively
charged nylon membrane and immunoblotted with 1 g/ml anti-
GXM antibody 3C2 as described in reference 49.
Protein purification and localization. Protein purification was per-
formed at 4°C using a previously described method (50) with some mod-
ifications. Cells were grown overnight in 50 ml of YPD to late log phase,
harvested by centrifugation (3,000  g, 10 min, RT), washed once with
cold Tris-EDTA buffer (100 mM Tris-HCl, pH 7.5, 0.1 mM EDTA), and
resuspended in an equal volume of the same buffer containing protease
inhibitors (0.1 mM phenylmethylsulfonyl fluoride and protease inhibitor
cocktail [10 l/ml; P8215; Sigma]). All subsequent steps were performed
at 4°C. Aliquots (800l) were transferred to 2-ml screw-cap microcentri-
fuge tubes and mixed with an equal volume of 0.5-mm glass beads (Bio-
Spec Products), and the samples were subjected to 1-min bursts on a
Mini-BeadBeater (BioSpec Products) alternating with 2 min on ice. Eight
to 10 cycles of bead beating were required to disrupt75% of the cells (as
assessed by microscopy). The lysate was then transferred to a 15-ml con-
ical tube, the glass beads were rinsed twice with 800 l of Tris-EDTA
buffer, and both rinses were pooled with the lysate. The pooled material
(total protein) was subjected to a low-speed clearing centrifugation step
(1,000  g, 25 min). The resulting cell-free supernatant fraction (S1; cy-
tosol and membranes) was removed, and the pellet (P1) was stored at 4°C
for later extraction. S1 was next fractionated by ultracentrifugation
(60,000 g, 45 min); the supernatant fraction from this step (S2; cytosol)
was reserved, and the pellet (P2; total membranes) was resuspended in 200
l of Tris buffer (100 mM Tris-HCl, pH 7.5) for detergent extraction of
membrane proteins (see below). Protein concentrations were determined
using a protein assay kit (catalog no. 500 0006; Bio-Rad Laboratories Inc.).
For Triton X-100 (TX-100) extraction of membrane proteins, P2 was
extracted with 1% TX-100 on ice for 1 h with brief vortex mixing every 5
min. Particulate material was removed by ultracentrifugation (60,000 g,
45 min), and both the pellet (TX-100-insoluble) and supernatant (TX-
100-soluble) fractions were stored at 4°C. A parallel P2 sample was ex-
tracted with 1% SDS by boiling for 10 min, after which the sample was
centrifuged (15,000 g, 10 min, RT) and the supernatant and pellet were
saved as SDS-soluble and SDS-insoluble fractions, respectively. Detergent
was removed by using an SDS-PAGE cleanup kit (GE Healthcare) before
protein gel electrophoresis. The cell wall-associated proteins were ex-
tracted as described in reference 51. Briefly, fraction P1 (see above) was
resuspended in 1 ml of Tris buffer and disrupted by probe sonication (5
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cycles of 10 s on and 10 s off; output, 35%). The sample was then centri-
fuged at 3,500 g for 10 min, and the pellet was washed three times with
Tris buffer, resuspended in 1 ml of lysing enzyme (20 mg/ml in diH2O
with protease inhibitors, as described above; L1412; Sigma), and rotated at
37°C for 1 h. After digestion, the sample was centrifuged at 15,000 g for
15 min and the supernatant was preserved as cell wall-extracted proteins.
Macrophage phagocytosis assay. To measure uptake by macro-
phages, we used our previously published assay (52) with minor modifi-
cations. As host cells we used the human monocytic cell line THP-1, which
was seeded onto 12-mm coverslips at a density of 2.5  105 cells/ml in
medium containing 0.2 g/ml of phorbol myristate acetate (PMA) to
induce differentiation. After 48 h, the medium was replaced with fresh
medium containing PMA to remove any nonadherent and dead cells, and
1 day later, uptake of serum-opsonized C. neoformans (multiplicity of
infection, 5) was measured. Coverslips were fixed and stained as described
previously (52), except that DAPI (4=,6-diamidino-2-phenylindole)
staining was omitted and CellMask plasma membrane dye was used in
place of CellMask HCS stain, and samples were imaged on a Zeiss LSM
510 confocal laser scanning system. At least 100 THP-1 cells were exam-
ined for each sample, and significance was evaluated by the Holm-Sidak
method with alpha equal to 1%.
RESULTS
Screening for capsule mutants. Our previous work showed that
cell wall -glucan is required for capsule association with C. neo-
formans cells (26, 27). We hypothesize that additional cellular el-
ements are also required for the normal display of capsule on the
cell surface. To identify such factors and further define the mech-
anism of capsule association in C. neoformans, we used a forward
genetic approach, screening for mutants defective in either surface
capsule display or the ability to donate capsule material to acap-
sular acceptor cells.
We tested surface capsule by labeling cryptococcal cells with an
anti-GXM monoclonal antibody (3C2, kindly provided by Tom
Kozel) and observing them by immunofluorescence microscopy
(see Materials and Methods). As shown in Fig. 1 (left two col-
umns), this antibody binds evenly to the cell surface of wild-type
cells but does not label strains known to be acapsular (such as
cap59 or ags1mutants). We tested the ability of cryptococci to
donate capsule (26) by collecting conditioned medium (CM)
from cultures of the strains of interest and incubating it with cells
of the acapsular cap59 mutant. We then washed the acceptor
cells and used the 3C2 antibody to assess their acquisition of cap-
sule material from the donor CM (see Materials and Methods).
CM from wild-type cells was an effective donor of capsule material
to the cap59 mutant in this assay, while CM from the cap59
mutant itself could not act as a donor (Fig. 1, right two columns).
CM from cells of the ags1 mutant was transfer competent, al-
though the mutant itself bore no capsule, showing that the defect
in the ags1 mutant is one of capsule association with the cell
surface, rather than a problem with capsule synthesis or release
(Fig. 1) (27).
We screened the 1,201 strains in a C. neoformans deletion col-
lection generated by the Madhani laboratory (31) and identified
13 with consistent differences in surface capsule or capsule trans-
fer compared with wild-type C. neoformans (Table 2 and data not
shown). Four known acapsular mutants, the CAP10, CAP59,
CAP60, and CAP64 mutants, were negative for surface capsule, as
shown previously (53–56), and for the ability to donate capsule
material. A similar profile was seen in cells lacking an enzyme
(Ugd1) required for the production of UDP-glucuronic acid and
UDP-xylose; these molecules are important sugar donors for cap-
sule polysaccharide synthesis (57–59). Several other mutants
showed partial defects in the ability to donate capsule or in their
surface capsule, but we were particularly interested in three strains
that bore a surface capsule, as detected by antibody staining, but
were not able to donate capsule in our transfer assay (Table 2, bold
font). This phenotype was opposite that of the ags1mutant cells,
which do not display surface capsule but do shed capsule that can
bind normally to acapsular cells (26). It suggested that these mu-
tants (Table 2, bold font) made polysaccharide that could associ-
ate with the cells of origin but had some defect that precluded
appreciable binding to acapsular cells. Findings for one of these
mutants, the cpl1 mutant, will be presented elsewhere (Meng
Yang and Tamara L. Doering, unpublished data). Below we pres-
ent our findings on the other two mutants, the pbx1 and pbx2
mutants.
In previous studies of the pbx1 and pbx2mutants, the miss-
FIG 1 Detection of cell surface capsule and capsule transfer. (Left two col-
umns) Endogenous surface capsule of the indicated strains was probed by
staining with the anti-GXM monoclonal antibody 3C2. (Right two columns)
The cap59 acapsular strain was used as the acceptor for exogenous capsule
from CM of the indicated strains, washed, and stained similarly. The left panel
of each pair is a differential interference contrast (DIC) image, and the right
panel is an immunofluorescence (IF) image. All images are at the same mag-
nification. Bar
 5 m.
TABLE 2 Capsule phenotypes of C. neoformans mutant strains
Locus deleted
(CNAGa no.) Protein encoded
Cell surface
capsule
Capsule
donor
None  
02628 Cap10  
00721 Cap59  
00600 Cap60  
02885 Cap64  
04969 Ugd1  
06813 Cap1 / /
00440 Ssn801  /
06889 Na/H antiporter  /
06902 Hypothetical  /
05258 Hypothetical  /
02797 Cpl1  
01172 Pbx1  
05562 Pbx2  
03120 Ags1  
a CNAG, Cryptococcus neoformans assigned gene number (see
http://www.broadinstitute.org/annotation/genome/cryptococcus_neoformans).
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ing proteins were implicated in capsule synthesis (32), although
capsule transfer was not assessed at that time (see Discussion). To
further address their function, we first replaced PBX1 and PBX2 in
the serotype A strain KN99with sequences that confer resistance
to G418 and nourseothricin, respectively (37, 38). KN99 is
closely related to the strain that was used to generate the mutant
library (H99) but is more genetically tractable (33). We confirmed
the new mutant strains (Table 1) by PCR and DNA blotting (data
not shown) and tested them for surface capsule: as expected from
our screen results, anti-GXM antibody staining of both mutants
was similar to that of wild-type cells (Fig. 2A). Also consistent with
our earlier results, CM harvested from cultures of the pbx1 or
pbx2mutant failed to donate capsule to the cap59mutant; the
same result was obtained with a double mutant (the pbx1 pbx2
mutant) that we generated by deleting the PBX2 gene in a pbx1
mutant background (Fig. 2B, left two columns). Complementa-
tion of the mutants by reintegration of the wild-type sequences
(pbx1::PBX1 and pbx2::PBX2) restored normal capsule trans-
fer (Fig. 2B, right two columns).
GXM release. We wondered whether the inability of cells lack-
ing Pbx1 and Pbx2 to act as capsule donors was due to the nature
or amount of shed GXM. To test this, we performed standard
capsule transfer assays in the presence of increasing concentra-
tions of CM. At the standard CM dilution of 1:500, we observed no
transfer of polysaccharide from mutant CM to acapsular acceptor
cells, although wild-type CM showed a robust signal at this dilu-
tion (Fig. 3); similar results were obtained with a 1:20 dilution of
CM. Notably, use of undiluted CM did result in transfer to cap59
mutant cells, although the capsule staining of the acceptor cells
was not as complete as that with wild-type CM, demonstrated by
an uneven and patchy signal (Fig. 3). These studies showed that
mutant capsule could bind to acapsular cells, albeit poorly, but did
not establish whether the underlying defect was a reduced amount
of shed GXM in the CM or a reduced affinity of the polysaccharide
material for the acapsular acceptor cells due to some fundamental
change.
To directly examine the GXM that was shed from pbx mutant
cells, we compared the polysaccharide-containing CM from each
single mutant to that from the wild type by resolving the material
on agarose gels and immunoblotting with anti-GXM 3C2 anti-
body (49). CM from the pbx mutant strains contained minimal
antibody-reactive material compared to that from equal volumes
of wild-type CM (Fig. 4, left); this material could be detected only
on long exposures of the immunoblots (see Fig. S2 in the supple-
mental material). Similar analysis of CM from cultures grown in
capsule-inducing medium (see Materials and Methods) showed
slightly more GXM in the mutant CM, although this amount was
still significantly less than that seen in wild-type CM (Fig. 4, cen-
ter). (The growth rates of all strains were comparable in both
media; see Fig. S3 in the supplemental material.) Because this
analysis was based on antibody detection, we considered the pos-
sibility that the reduced signal might reflect altered interactions of
mutant GXM with the 3C2 antibody. To test this, we purified
GXM from each strain and compared equivalent mass amounts in
a parallel blotting experiment. In this study, the GXM from all
strains appeared to be identical in both signal intensity and gel
migration behavior (Fig. 4, right). Furthermore, the purified
GXM from each mutant showed the same efficacy as a capsule
donor as wild-type purified GXM when comparable masses were
included in transfer assays (not shown). Together, these experi-
ments suggest that the poor function of pbx mutants as capsule
donors does not reflect a difference in their GXM size (as assessed
by gel electrophoresis) or structure (as assessed by antibody reac-
tivity) but, rather, reflects a reduction in the amount of polysac-
FIG 2 pbx strains display cell surface capsule but cannot donate capsule to
acapsular acceptor cells in standard assays. (A) Surface capsule. Cells of the
indicated strains were labeled with antibody 3C2 and imaged as described in
the legend to Fig. 1. (B) Capsule transfer. CM from the indicated strains (or
YPD alone as a control) was used as the capsule donor in transfer assays, with
the cap59mutant as the acceptor strain. Imaging is as described in the legend
to Fig. 1. 1, pbx1mutant; 2, pbx2mutant; 1::1, pbx1mutant comple-
mented with PBX1; 2::2, pbx2 mutant complemented with PBX2; 12,
pbx1 pbx2mutant. All images in both panels are at the same magnification.
Bar
 5 m.
FIG 3 pbx mutants are poor capsule donors in transfer experiments.
Capsule transfer assays were performed as described in the legend to Fig. 2,
using the indicated dilutions of CM from the strains noted at the left (the
1:500 dilution is that used in the standard assay; see Materials and Meth-
ods). Bar 
 5 m.
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charide that is shed from the mutant cells during growth in cul-
ture.
Intracellular GXM. The observed reduced shedding of GXM
could indicate either a defect in the production of this polysaccha-
ride or a failure to release it into the medium. To distinguish
between these possibilities, we probed thin sections of cryptococ-
cal cells with a colloidal gold-tagged monoclonal antibody to
GXM (2H1). The resulting immunoelectron micrographs (Fig. 5)
showed abundant labeling of wild-type cell surfaces with occa-
sional intracellular signal, especially on vesicular structures. In
contrast, the pbx1, pbx2, and pbx1 pbx2 mutant strains
showed less surface staining and no intracellular signal, consistent
with a general reduction in GXM synthesis. Although reduced
surface staining together with reduced shedding could also occur
if the cells had a defect in secretion of capsule polysaccharide, we
would expect such cells to demonstrate a corresponding increase
in intracellular signal (24); the absence of any internal signal in the
mutants, let alone such an increase (Fig. 5 and data not shown),
further supports a defect in capsule polysaccharide synthesis.
Surface capsule. Our analysis of shed GXM (Fig. 4) suggested
that the release of polysaccharides from pbx mutants increased in
capsule induction medium. To examine the induction of cell-as-
sociated capsule polysaccharides, we grew cells under inducing
conditions (in DMEM with 5% CO2 at 37°C; see Materials and
Methods) and assessed capsule size by negative staining with India
ink. Upon induction, all of the pbx mutants produced capsules
with a radius similar to that of the wild type (see the top row of Fig.
S4 in the supplemental material), although the mutant capsules
were more heterogeneous in thickness (data not shown).
We further examined the capsule structure of cells grown un-
der inducing conditions using quick-freeze deep-etch imaging. As
we showed previously (25), the capsule fibers of wild-type cells
grown in this way form a dense meshwork extending from the cell
wall. In contrast, the pbx mutant capsules formed a much looser
network (Fig. 6). The association between the capsule and wall was
also weaker, as brief sonication was sufficient to release almost all
of the capsule material from pbx1, pbx2, and pbx1 pbx2
mutant cells, even though wild-type capsules were not perturbed
by this treatment (see the bottom row in Fig. S4 in the supplemen-
tal material). This phenotype, which is consistent with results pre-
viously reported by Liu et al. for pbx1 and pbx2mutants (32),
was reversed upon complementation with the corresponding
wild-type genes (see Fig. S4 in the supplemental material).
Capsule polysaccharide analysis. The loose association of the
capsule with the cell surface of pbx mutants could be due to
differences in either the capsule itself or the underlying cell wall.
Previous studies of cells lacking PBX1 and PBX2 reported that
GXM in these mutants contained glucose (which the wild type
FIG 4 pbxmutants are deficient in capsule shedding. Shown are the results
of immunoblot analysis of CM or purified GXM from the indicated strains
grown in rich medium (YPD) or CIM. Samples (50l of CM or 10g of GXM)
were resolved by agarose gel electrophoresis and immunoblotted with anti-
body 3C2. The exposure time was 2 s (images after a longer exposure are shown
in Fig. S2 in the supplemental material). The reduced migration of GXM from
cells grown in CIM reflects the increased polymer size that results from capsule
induction (49).
FIG 5 pbxmutants show reduced intracellular and surface capsule polysac-
charide. Cryptococcal cells grown in YPD medium were examined by immu-
noelectron microscopy using colloidal gold-labeled anti-GXM monoclonal
antibody 2H1. Each panel shows a portion of a cell of the indicated strain. All
images are at the same scale. Bar
 500 nm.
FIG 6 The capsules of pbx mutants have reduced density. Quick-freeze,
deep-etch electron micrographs for the indicated strains are shown. Each im-
age shows a portion of the cell edge, with the plasma membrane at the top and
capsule fibers at the bottom (extending downwards) separated by the cell wall.
All strains were grown under the same conditions, and all images are at the
same magnification. Bar
 100 nm.
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does not), but the chemical structure of the mutant polysaccharide
was not determined (32). To pursue this observation, we purified
GXM from pbx1 mutant, pbx2 mutant, and wild-type cells for
NMR analysis (see Tables S2 and S3 in the supplemental material). All
three samples were composed of structures corresponding to man-
nosyl triads M2 and M3 (Fig. 7), although the fraction of M3 was
higher in the mutant strains than in the wild type (Table 3). This
difference would correspond to an additional 25% of GXM reporter
groups containing xylose-1,4 linked to the backbone mannose res-
idue that also bears glucuronic acid (ManA in Fig. 7), translating to an
overall increase in GXM xylose of 10%. We did not detect any
glucose in the GXM structure (see Discussion).
To further characterize GXM purified from mutant and wild-
type strains, we determined its molecular mass using multiangle
light scattering (MALS). The masses of all three strains were very
similar to each other (Table 4) and to the masses typical for sero-
type A strains (13). The slightly higher masses of the mutant GXM
may reflect the presence of the modestly increased amount of
xylose detected by NMR.
We also purified the second capsule polysaccharide, GXMGal,
from wild-type and mutant strains of C. neoformans. For this
study, we deletedPBX1 andPBX2 in a cap59mutant background
to avoid contamination of the GXMGal preparations with the
more abundant GXM produced by wild-type cells. The composi-
tions of mutant and wild-type GXMGal were very similar (Table
5), suggesting no alterations that could be attributed to the lack of
Pbx proteins. We also used these samples for NMR determination
of the GXMGal structure, as this has not been reported for acap-
sular serotype A strains. While the basic structure is similar to that
reported for serotype D strains, the serotype A polymer contains
more galactofuranose (data not shown) and exhibits more 2-acet-
ylation of mannose residues (see Table S4 in the supplemental
material). Overall, these studies suggested that the structures of
both capsule polysaccharides in the pbxmutant strains are close to
those of the wild type, although the amount of shed GXM is sig-
nificantly reduced. These results are consistent with our observa-
tion that GXM purified from mutant strains binds normally to
acapsular acceptor cells (not shown).
Cell wall analysis. Because the relatively modest differences in
the capsule polysaccharide structure of the pbx mutants may not
be enough to explain the defects in capsule association with the
cell wall (revealed by sonication), we examined the latter structure
more closely. Cell wall-perturbing agents such as SDS, calcofluor
white, and Congo red did not alter the growth of the mutant
compared to that of the wild type (data not shown), suggesting
normal overall cell integrity. We also compared the morphology
of mutant cells to that of wild-type cells. Although the mutants
exhibited no alterations in the thickness or general appearance of
the cell wall when assessed at high magnification by thin-section
electron microscopy (not shown), lower-magnification views
showed that the cells were less regular in shape than wild-type or
complemented mutant cells. While most wild-type or comple-
mented mutant cells were round and smooth surfaced, the mu-
tants showed asymmetric and uneven boundaries (Fig. 8). In
other phenotypic changes that are potentially related to the cell
wall, the pbx1, pbx2, and pbx1 pbx2mutants showed mod-
est defects in the production of cell wall melanin, and the pbx1
pbx2 double mutant showed reduced production of mating fil-
aments (see Fig. S5 and S6 in the supplemental material). These
cells also displayed heightened sensitivity to oxidative stress (Fig.
9), which has been related to cell walls in yeasts (60, 61).
Pbx protein localization. The Pbx proteins are predicted to
have transmembrane domains and localize to membranes (Fig. S8
in the supplemental material). Consistent with this, immunoblot-
ting analysis of HA-tagged versions of Pbx1 and Pbx2 expressed in
C. neoformans showed that both proteins were completely absent
from the cytosolic fraction (Fig. 10). The proteins were not ex-
tracted from membranes by 1% Triton X-100 (4°C, 1 h), although
they could be extracted with 1% SDS (100°C, 10 min), and they
FIG 7 GXM structural motifs. The two structural reporter groups that were
detected in GXM of wild-type strain KN99 and mutant strains are shown;
GXM is composed of multiple repeats of these motifs. Superscripts denote
specific residues for reference to the structural information provided in Tables
S2 and S3 in the supplemental material.
TABLE 3 Molar ratios of the mannosyl triads detected in GXM from
WT and mutant strains
Triad
Molar ratio
WT KN99 pbx1mutant pbx2mutant
M2 85 63 60
M3 15 37 40
TABLE 4 Molecular masses for purified GXM derived from MALS
analysis
GXM source dn/dc constant Molecular mass (Da)
WT KN99 0.173 1.578 106
pbx1mutant 0.157 1.635 106
pbx2mutant 0.167 1.636 106
TABLE 5 GXMGal glycosyl composition
Monosaccharide
Composition
cap59mutant
cap59 pbx1
mutant
cap59 pbx2
mutant
Mass
(g) mol%
Mass
(g) mol%
Mass
(g) mol%
Xylose 72.6 15.5 278.5 12.9 116.4 14.1
Glucuronic acid 10.3 1.7 101.5 3.6 15.7 1.5
Mannose 122.0 21.7 576.8 22.3 235.1 23.7
Galactose 342.4 61.0 1,580.3 61.1 603.9 60.8
Total 547 100 2,537.1 100 971.2 100
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were not associated with cell wall fractions (Fig. 10). These char-
acteristics suggest that they are located in detergent-resistant
membranes (see Discussion).
Host cell interaction. Finally, we investigated the interactions
of the pbx mutant strains with host phagocytes, which have been
implicated in fungal latency and dissemination, in addition to
host defense. We found that phagocyte engulfment of these strains
was increased by about 50% compared to the level of internaliza-
tion of wild-type cells (Fig. 11; P 
 2.2  1010). This may con-
tribute to the reduced virulence of single pbx mutants that has
previously been reported (32) (see Discussion).
DISCUSSION
The cell wall of C. neoformans is required for fungal integrity, and
its polysaccharide capsule is critical for pathogenesis (12, 23, 62,
63). Although these two key structures are physically linked, the
mechanism of their association is only poorly understood. In pre-
vious work, we developed a capsule transfer assay to assess the
ability of capsule polysaccharides shed from donor cells to bind to
the cell walls of acapsular mutant acceptor cells. This enabled us to
identify cell wall -glucan as an important attribute of the accep-
tor cell walls which was needed for cell surface display of capsule
polysaccharides (26, 27). We hypothesized that characteristics of
the donor cell would also contribute to this process. To identify
such features, we screened a deletion collection generated by the
Madhani group (31) for mutants that could not effectively func-
FIG 8 pbx mutants show irregular cell morphology. Thin-section electron
micrographs in the top row are all at the same magnification, and images in the
bottom two rows are all at the same (lower) magnification. Bars
 1 m.
FIG 9 pbx1 pbx2mutant cells show increased sensitivity to oxidative stress.
Serial 10-fold dilutions were spotted on yeast nitrogen base agar containing 1
mM H2O2 and grown at the indicated temperatures for 4 days.
FIG 10 Pbx proteins occur in detergent-resistant membranes. Total cell lysate
cleared of cell debris (S1) was subjected to ultracentrifugation, and the super-
natant fraction (S2) was removed. The pellet (P2) was extracted with TX-100
or SDS and fractionated into detergent-insoluble (Insol.) and detergent-solu-
ble (Sol.) fractions. The cell wall-containing fraction (P1) was treated with
lysing enzyme and fractionated into supernatant (Sup.) and pellet fractions.
The same number of cell equivalents of each fraction of the indicated strains
was resolved by SDS-PAGE and immunoblotted with anti-HA antibody. See
Materials and Methods for details.
FIG 11 C. neoformans lacking Pbx1 is more efficiently engulfed by human
phagocytes than wild-type fungi. (Top) Plot showing the 1.5-fold increase in
uptake of the pbx1 mutant by THP-1 cells compared to that of wild-type
fungi (mean values, 192 and 129 fungal cells/100 host cells, respectively). (Bot-
tom) Confocal images of cryptococci (cell walls stained green) engulfed by
THP-1 cells (the cytosol stained red). Left column, wild type; right column,
pbx1 mutant. In some instances, fungi appear outlined in yellow in the
merged image; this is because of pixel overlap with the intense cytosolic stain.
Results are representative of those from two independent experiments. All
images are at the same scale. Bar
 10 m.
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tion as capsule donors in our transfer assay. In parallel, we assessed
the surface capsule of these strains.
Our screen identified several strains with an impaired ability to
serve as capsule donors and two groups of mutants that were com-
pletely unable to do so. One of these groups included four Cap
mutants that have previously been characterized to be acapsular
(53–56), along with another strain that we previously showed has
an acapsular phenotype (ugd1) (58). Our identification of these
strains, which, as expected from the literature, also lacked surface
capsule (Table 2), validated our screening approach.
A second group of interesting mutants included strains that
were unable to serve as capsule donors, even though they did
display surface capsule (Table 2). This report describes our find-
ings on two of these strains, the pbx1 and pbx2mutants, which
have indistinguishable phenotypes. Compared to wild-type cells,
both mutants have less dense arrays of capsule fibers and capsules
that are more loosely associated with the cell wall. The pbx mu-
tants also shed greatly reduced amounts of capsule compared to
the wild type, which accounts for their transfer defect. This most
likely reflects a global defect in synthesis, because capsule material
within the cell and at the cell surface is also reduced (Fig. 5). Both
pbx mutants also displayed an aberrant cell wall morphology and
exhibited some mild phenotypes associated with cell wall dysfunc-
tion that were more severe in the double mutant. pbx mutant cells
were also engulfed more avidly than wild-type cells by human
phagocytic cells, a process that has been implicated in host defense
as well as fungal latency and dissemination. In some scenarios,
residence within host cells may benefitC. neoformans. However, in
the context of mutant cells that have deformed cell walls and in-
creased sensitivity to oxidative stress, this engulfment is likely a
dead end, and the increased phagocytosis may contribute to the
observed virulence defect of cells lacking Pbx proteins (32).
Pbx1 and Pbx2 have parallel beta-helix domains, like cell wall-
degrading enzymes such as pectin lyase, homogalacturonase, and
xyloglucanase. Despite significant effort, we were unable to di-
rectly demonstrate glucanase activity for these proteins (see the
text in the supplemental material). One possibility is that the Pbx
proteins act to remodel the cell wall, liberating sugars for other
synthetic processes. According to this model, the cell wall would
overgrow in the absence of Pbx1 and Pbx2 at the expense of cap-
sule synthesis; the abnormal wall would also mediate looser asso-
ciations with the capsule. This model is consistent with the phe-
notypes that we observed in the pbx mutants, including their
aberrant morphology (Fig. 8), less dense capsules (Fig. 5) that are
easily released from the cell surface (32) (see Fig. S4 in the supple-
mental material), and a reduction in capsule shedding (Fig. 4) and
the resultant transfer (Fig. 2 and 3). Based on the identical pheno-
types of the two mutants and defects that were generally more
severe in the double mutant, we believe that Pbx1 and Pbx2 serve
redundant functions, although confirmation of this would require
additional investigation.
In addition to the gross morphological changes in pbx mutant
cell walls (Fig. 8), we observed several more subtle alterations sug-
gesting cell wall abnormalities. The pbx1 and pbx2 mutants
showed decreased production of melanin (see Fig. S5 in the sup-
plemental material), which occurs at the cell wall, and heightened
binding of the cell wall stain lucifer yellow (data not shown). The
double mutant was further defective in generating mating struc-
tures (see Fig. S6 in the supplemental material). Interestingly,
none of the mutants differed from the wild type in sensitivity to
calcofluor white and Congo red (not shown), two dyes typically used
to assess cell wall integrity (64). Since these compounds bind with the
highest affinity to chitin (65), this suggests that cell wall chitin is nor-
mal in the pbx mutants. Supporting this suggestion, these com-
pounds and several other reagents that bind to related cellular com-
ponents, including wheat germ agglutinin (N-acetylglucosamine),
pontamine (chitin and chitosan), and eosin Y (chitosan), bind simi-
larly to mutant and wild-type cells (not shown).
Additional support for our hypothesis that Pbx proteins act in
cell wall remodeling comes from their localization in detergent-
resistant membranes (Fig. 10), also termed lipid rafts (66). There
is significant precedent in fungi for membrane proteins playing
critical roles in cell wall assembly and morphogenesis; examples
include Saccharomyces cerevisiae, Neurospora crassa, and Aspergil-
lus fumigatus (67–69).
Our model suggests that the absence of Pbx proteins leads to
reduced cell wall remodeling, which has consequences for cell
morphology and capsule association. This would also alter the
metabolic balance of the cells and the substrates available for syn-
thesis of glycans, potentially explaining the reduced capsule poly-
saccharide synthesis of the pbx mutants. Metabolic imbalance
might also explain the slightly increased xylosylation of the mu-
tant capsule polysaccharide. Although xylose is incorporated into
cryptococcal glycoproteins (70, 71), it is a relatively minor com-
ponent of the cell wall overall, whereas it plays a major role in
capsule polysaccharides. Reduced wall turnover might therefore
have a lesser effect on this capsule moiety than on mannose, for
example, which is a major component of both structures, leading
to the altered ratio of these components that we observed in GXM.
We tried hard to demonstrate a specific biochemical activity
for the Pbx proteins by growth on various substrates, in vitro
assays using cell lysates or purified proteins, and several phys-
ical methods for assessing protein-glycan binding (see the text
in the supplemental material). Our inability to do this may
have several explanations. The cell wall of C. neoformans differs
from that of other model yeast, and there is precedent for this organ-
ism having unique glycan structures; cryptococcal glycans have
also not been fully characterized. We may therefore not have tested
the appropriate substrates. It is also possible that a lipid association
of these membrane proteins is required for their function. Finally,
our glycan array binding studies were based on the currently avail-
able array (version 5.0; http://www.functionalglycomics.org/static
/consortium/resources/resourcecoreh16.shtml), which is primarily
composed of mammalian glycans, so we may not have had access
to the appropriate binding partner. As we learn more about cryp-
tococcal glycobiology and the community develops additional
fungal glycan reagents, we will be able to productively revisit these
experiments.
On the basis of compositional analysis of GXM, it was previ-
ously proposed that Pbx proteins act to remove glucose residues
that are aberrantly incorporated into capsule polysaccharides
(32). Our analysis of the composition of GXM and GXMGal from
wild-type and mutant cells and detailed determination of their
structures by NMR do not indicate the presence of any glucose
and therefore do not support this model. GXM preparations may
be contaminated with cell wall glucans, particularly when the
strain being analyzed has low levels of shed capsule polysaccha-
rides (unpublished observations), as is the case for the pbx mu-
tants. The presence of cell wall glucans may have led to the previ-
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ous observation of glucose in capsule polysaccharide samples
from these strains.
We conclude that Pbx proteins act in C. neoformans cell wall
remodeling. Their absence leads to an abnormal cell wall struc-
ture, which impairs capsule association, and altered metabolic
balance, which reduces capsule polysaccharide synthesis. These
changes yield cells that are less fit to cause disease, as demonstrated
by their lack of virulence (32). Future work will be needed to
demonstrate a specific biochemical function for these intriguing
enzymes; this may require lipid reconstitution and further defini-
tion of cryptococcal glycans to suggest potential substrates. None-
theless, our work has demonstrated the interplay between cell wall
and capsule synthesis and elucidated how perturbations in these
processes critically affect the virulence of this deadly pathogen.
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